Quarterly ResultMay 6, 2026, 07:33 AM
Bioventus Q1 Revenue +7% to $132.1M; Raises FY26 EPS & Cash Guidance
AI Summary
Bioventus reported a strong Q1 2026 with revenue increasing 7% to $132.1 million, driven by growth across all business segments. GAAP earnings improved significantly to $0.04 per diluted share from a prior-year loss, and non-GAAP earnings rose 88% to $0.15 per diluted share. The company also generated $8.9 million in cash from operations, a substantial increase from a prior-year outflow. Consequently, Bioventus raised its full-year 2026 non-GAAP EPS and Cash from Operations guidance, while reaffirming its revenue outlook.
Key Highlights
- Q1 2026 revenue increased 7% to $132.1 million.
- GAAP earnings were $0.04 per diluted share, compared to a $0.04 loss in prior year.
- Non-GAAP earnings rose 88% to $0.15 per diluted share.
- Cash from operations was $8.9 million, up $28.3 million from prior year outflow.
- Raised full-year 2026 Adjusted EPS guidance to $0.75-$0.79, an increase of $0.02.
- Raised full-year 2026 Cash from Operations guidance to $84M-$89M, an increase of $2M.
- Pain treatments revenue grew 7.7% to $63.4 million.
- Made a $22.0 million discretionary principal prepayment on its term loan.